Featured Research

from universities, journals, and other organizations

Widely Used Anti-Bacterial Inhibits Parasites That Cause Malaria And Toxoplasmosis

Date:
February 12, 2001
Source:
University Of Chicago Medical Center
Summary:
Triclosan, a common antiseptic used in household products such as toothpaste, skin creams, and deodorants, kills the parasites responsible for malaria and toxoplasmosis, even at very low concentrations, reports a team of researchers from the United States and the United Kingdom in the February issue of the International Journal for Parasitology.

Triclosan, a common antiseptic used in household products such as toothpaste, skin creams, and deodorants, kills the parasites responsible for malaria and toxoplasmosis, even at very low concentrations, reports a team of researchers from the United States and the United Kingdom in the February issue of the International Journal for Parasitology.

Triclosan has been used as an antiseptic since the 1960s. It blocks an enzyme, known as "FabI," that bacteria need to manufacture the fatty acids used in cell membranes. Because animals possess a very different set of enzymes, triclosan does not interfere with this process in humans. This has led to its widespread use in over-the-counter preparations used on the skin or in the mouth.

“This common, inexpensive antimicrobial is remarkably effective against these parasites at concentrations that have no detectable toxicity,” said first author Rima McLeod, M.D., the Jules and Doris Stein Research to Prevent Blindness Professor of Ophthalmology and Visual Sciences at the University of Chicago.

"That's good news because we urgently need new and better medicines to treat malaria and toxoplasmosis," she added. "The parasites that cause malaria are resistant to many of the available drugs, and there is no medication that affects the latent life-cycle stages of the parasite that causes toxoplasmosis."

"This finding gives us a blueprint to design an effective and safe new drug," said co-author Craig Roberts of the University of Strathclyde, UK."

Malaria affects more than 300 million people worldwide and kills an estimated 3,000 people, mostly children, each day. Although most cases originate in the tropics, there has been a steady increase in U.S. and European reports of "airport malaria" cases involving people who come down with the disease without ever visiting the tropics.

An estimated 30 percent of Americans are infected with the parasite, spread by cats, that causes toxoplasmosis. Although it is usually harmless, Toxoplasma gondii can cause devastating problems for those with weakened immune systems or when transmitted from mother to unborn child. About 3,000 infants are born each year in the U.S. with toxoplasmosis. The disease can cause severe eye damage, mental retardation and death. The cost of caring for these children is estimated to exceed $500 million per year.

The parasites that cause these diseases are members of the phylum Apicomplexa. Three years ago, McLeod’s team discovered that the organisms in this phylum all shared genes for a plant-like metabolic pathway, and that the herbicide glyphosate ("Roundup") interfered with part of that pathway, inhibiting parasite growth and survival.

The current study shows that these parasites also have a FabI that was very similar to the bacterial or plant form of the enzyme, and that triclosan at low concentrations was extremely effective against these parasites in tissue culture, without harming the host cells. Triclosan was even effective against strains of the malarial parasite, Plasmodia falciparum, that had developed resistance to established anti-malarial medications noted co-authors Dennis Kyle and Wil Milhous from Walter Reed Army Institute of Research in Washington, DC.

"These findings may provide novel ways to counteract the increasing resistance of Plasmodia to the current armory of antimalarial agents and provide a new approach to the great need for additional, less toxic antimicrobial agents effective against toxoplasmosis," note the authors.

The researchers suggest that triclosan could be combined with other plant- and bacterial-enzyme inhibitors they are investigating to disrupt fatty acid synthesis at multiple points, a strategy that could prevent or delay the development of resistant microbes.

David Rice and John Rafferty are members of the Department of Molecular Biology and Biotechnology at the University of Sheffield and were key collaborators in this work. They have studied the structure of FabIs from plants and bacteria and found that the malarial enzyme is most similar to that from plants. The malarial FabI has the same pattern of critical amino acids that bind triclosan as the plant and bacterial variants.

Additional authors of the paper include Ernest Mui, Michael Kirisits and Douglas Mack from the University of Chicago; Benjamin Samuel from Northwestern University, in Chicago, and Stephen Muench from the University of Sheffield.

Funding support came from several sources including, from the US, the National Institutes of Health and Research to Prevent Blindness Foundation, and from the UK, the Wellcome Trust, the Biotechnology and Biological Sciences Research Council, and the Royal Society.


Story Source:

The above story is based on materials provided by University Of Chicago Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Chicago Medical Center. "Widely Used Anti-Bacterial Inhibits Parasites That Cause Malaria And Toxoplasmosis." ScienceDaily. ScienceDaily, 12 February 2001. <www.sciencedaily.com/releases/2001/02/010206080902.htm>.
University Of Chicago Medical Center. (2001, February 12). Widely Used Anti-Bacterial Inhibits Parasites That Cause Malaria And Toxoplasmosis. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2001/02/010206080902.htm
University Of Chicago Medical Center. "Widely Used Anti-Bacterial Inhibits Parasites That Cause Malaria And Toxoplasmosis." ScienceDaily. www.sciencedaily.com/releases/2001/02/010206080902.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins